Urology · Raleigh, NC
NPI
1891786091
Since 2005
Specialty
Urology
Code 208800000X
Group practices
2
Medicare group memberships
Hospitals
3
Hospital affiliations
3821 ED Dr
Raleigh, NC, 27612
Phone (919) 758-8677
Groups this clinician bills Medicare through
Medicare paid, 2024
$409K
12,028 services
Medicare patients, 2024
593
Average age 76
Drug cost, 2024
$798K
2,057 prescriptions
Company payments, 2025
$82K
From 19 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by John V Kaspar was code J0585 (injection, onabotulinumtoxina, 1 unit), 4,600 times for 19 patients. In total John V Kaspar billed 12,028 services in 105 codes, and Medicare paid $409K.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2021-01-07.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| J0585 Injection, onabotulinumtoxina, 1 unit | Office | 4,600 | 19 | $4.99 | $23K |
| Q9967 Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | Office | 1,801 | 19 | $0.11 | $189 |
| 99214 Office E&M - Established | Office | 862 | 471 | $92.28 | $80K |
| 82570 Clinical Chemistry | Office | 823 | 461 | $5.08 | $4,177 |
| 51798 Ultrasound - Nonspecific | Office | 432 | 319 | $7.95 | $3,433 |
| 81003 Clinical Chemistry | Office | 416 | 279 | $2.20 | $913 |
| 81001 Clinical Chemistry | Office | 408 | 260 | $3.11 | $1,269 |
| G2211 Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's | Office | 225 | 166 | $13.24 | $2,978 |
| 84153 Clinical Chemistry | Office | 195 | 152 | $18.02 | $3,514 |
| 52000 Cystourethroscopy | Office | 154 | 136 | $153.77 | $24K |
| J9217 Leuprolide acetate (for depot suspension), 7.5 mg | Office | 148 | 15 | $140.88 | $21K |
| 99204 Office E&M - New | Office | 122 | 122 | $117.39 | $14K |
| 52442 Cystourethroscopy | Office | 112 | 21 | $670.56 | $75K |
| 99213 Office E&M - Established | Office | 99 | 90 | $66.54 | $6,588 |
| 95972 Electrical Nerve Conductivity | Office | 86 | 47 | $44.28 | $3,808 |
By year: 2022 $689K for 30,066 services; 2023 $462K for 19,165 services; 2024 $409K for 12,028 services.
Lab tests billed to Medicare, 2024
| Test code | Tests | Patients | Paid per test | Medicare paid |
|---|---|---|---|---|
| 82570 Clinical Chemistry | 823 | 461 | $5.08 | $4,177 |
| 81003 Clinical Chemistry | 416 | 279 | $2.20 | $913 |
| 81001 Clinical Chemistry | 408 | 260 | $3.11 | $1,269 |
| 84153 Clinical Chemistry | 195 | 152 | $18.02 | $3,514 |
| 84403 Clinical Chemistry | 75 | 48 | $25.29 | $1,897 |
| 82565 Clinical Chemistry | 21 | 20 | $5.02 | $105 |
Medicare prescription drug claims, 2024
In 2024, the drug John V Kaspar prescribed most often to Medicare patients was Gemtesa (Vibegron), with 337 prescriptions and refills. In total John V Kaspar wrote 2,057 Medicare prescriptions that cost $798K.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Gemtesa Vibegron | 337 | 585 | 96 | $275K |
| Dutasteride Generic | 224 | 603 | 76 | $5,524 |
| Ciprofloxacin Hcl Generic | 174 | 175 | 158 | $870 |
| Myrbetriq Mirabegron | 171 | 248 | 43 | $108K |
| Tamsulosin Hcl Generic | 102 | 276 | 37 | $1,310 |
| Hydrocodone-Acetaminophen Hydrocodone/Acetaminophen | 102 | 102 | 92 | $403 |
| Cephalexin Generic | 101 | 137 | 75 | $773 |
| Finasteride Generic | 83 | 244 | 30 | $1,229 |
| Estradiol Generic | 76 | 193 | 48 | $4,705 |
| Solifenacin Succinate Generic | 66 | 180 | 22 | $2,792 |
| Sulfamethoxazole-Trimethoprim Sulfamethoxazole/Trimethoprim | 54 | 85 | 36 | $346 |
| Potassium Citrate Er Potassium Citrate | 45 | 74 | 12 | $4,632 |
| Testosterone Cypionate Generic | 41 | 90 | 15 | $2,855 |
| Trospium Chloride Generic | 39 | 67 | 14 | $1,589 |
| Xtandi Enzalutamide | 30 | 30 | Under 11 | $272K |
Brand drugs: 580 claims; generic drugs: 1,465 claims; opioid claims: 108.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid John V Kaspar $82K ($82K in general payments such as food, travel and fees) from 19 companies. The largest payer was Teleflex LLC with $75K.
| Company | Payments | Amount |
|---|---|---|
| Teleflex LLC TFX | 76 | $75K |
| Sumitomo Pharma America, Inc. 4506.T | 10 | $3,663 |
| Dendreon Pharmaceuticals LLC | 45 | $2,006 |
| Medtronic, Inc. MDT | 10 | $725 |
| Boston Scientific Corporation BSX | 6 | $399 |
| Procept Biorobotics Corporation PRCT | 2 | $264 |
| Olympus America Inc. | 10 | $174 |
| Abbvie Inc. ABBV | 5 | $111 |
| Janssen Biotech, Inc. JNJ | 2 | $52.46 |
| Pfizer Inc. PFE | 2 | $48.5 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.